900522-23-8

Upstream product

• 900522-22-7 benzyl (2S,5R)-3-aza-5-(9H-9-fluorenylmethoxycarboxamido)-8-([(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]guanidino)-2-(2-methylpropyl)-4-oxooctanoate 

Downstream Products

• 900522-24-9 benzyl (2S,5R,8R)-3,6-diaza-8-(9H-9-fluorenylmethoxycarboxamido)-5-(3-([(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]guanidino)propyl)-12-(1,1-dimethylethoxycarbonylamino)-2-(2-methylpropyl)-4,7-dioxododecanoate 

Relevant academic research and scientific papers

Synthesis and antibacterial studies of binaphthyl-based tripeptoids. Part 1

An efficient synthesis of 29 new binaphthyl-based neutral, and mono- and di-cationic, peptoids is described. Some of these compounds had antibacterial activities with MIC values of 1.9-3.9 μg/mL against Staphylococcus aureus. One peptoid had a MIC value of 6 μg/mL against a methicillin-resistant strain of S. aureus (MRSA) and a MIC value of 2 μg/mL against vancomycin-resistant strains of enterococci (VRE).

PEPTIDIC COMPOUNDS

The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.